Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prednisolone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 10/20 | 0.93 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.93 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.93 |
| ▸ | PGR | P06401 | 5/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.93 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.93 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.93 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.93 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.93 |
| ▸ | TNF | P01375 | 1/20 | 0.93 |
| ▸ | IL6 | P05231 | 1/20 | 0.93 |
| ▸ | AR | P10275 | 1/20 | 0.93 |
| ▸ | GLUL | P15104 | 1/20 | 0.93 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.93 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.93 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.66 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prednisolone SCHEMBL1803463 | 0.99 | NR3C1 (0.91) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL28451307 | 0.97 | NR3C1 (0.91) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL2597917 | 0.96 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL765329 | 0.96 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL2737385 | 0.96 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL23863778 | 0.96 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL6566835 | 0.96 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL12396679 | 0.96 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL14420691 | 0.96 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL4449434 | 0.96 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5650170-A | Dosage form for delivering drug at a controlled rate to the intestine and to the colon | ALZA CORPORATION (US) | 1997-07-22 | — | — | US | claimed |
| US-20240423907-A1 | Improved Nasal Administration of Pharmaceutical Formulations | CYRANO THERAPEUTICS, INC. | 2024-12-26 | — | — | US | disclosed |
| CN-119113101-A | Methods of treating diffuse large B-cell lymphomas using anti-CD 79B immunoconjugates | 基因泰克公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-119012999-A | Improved nasal administration of pharmaceutical formulations | 思瑞诺医疗有限公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-4460284-A1 | IMPROVED NASAL ADMINISTRATION OF PHARMACEUTICAL FORMULATIONS | Cyrano Therapeutics, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| US-20240336697-A1 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | GENENTECH, INC. (US) | 2024-10-10 | — | — | US | disclosed |
| CN-118355029-A | Methods of treating diffuse large B-cell lymphomas using anti-CD 79B immunoconjugates | 基因泰克公司 | 2024-07-16 | — | — | CN | disclosed |
| EP-4380978-A1 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | Genentech, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| WO-2023133460-A1 | IMPROVED NASAL ADMINISTRATION OF PHARMACEUTICAL FORMULATIONS | CYRANO THERAPEUTICS, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| CN-115996703-A | Compositions and methods for treating ocular disorders by contact lens mediated drug delivery | 奇奥拉制药股份有限公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-0546038-B1 | DOSAGE FORM FOR TIME-VARYING PATTERNS OF DRUG DELIVERY | ALZA CORP (US) | 1994-07-27 | — | — | EP | disclosed |
| EP-0521074-B1 | DOSAGE FORM FOR DELIVERING DRUG TO THE INTESTINE | ALZA CORP (US) | 1994-03-02 | — | — | EP | disclosed |
| US-5232705-A | Hypotensive agents. vasodilators | ALZA CORPORATION (US) | 1993-08-03 | — | — | US | disclosed |
| EP-0546038-A1 | DOSAGE FORM FOR TIME-VARYING PATTERNS OF DRUG DELIVERY. | ALZA CORP (US) | 1993-06-16 | — | — | EP | disclosed |
| US-5178866-A | DOSAGE FORM FOR DELIVERING DRUG TO THE INTESTINE | ALZA CORPORATION (US) | 1993-01-12 | — | — | US | disclosed |
| EP-0521074-A1 | DOSAGE FORM FOR DELIVERING DRUG TO THE INTESTINE. | ALZA CORP (US) | 1993-01-07 | — | — | EP | disclosed |
| US-5156850-A | DOSAGE FORM FOR TIME-VARYING PATTERNS OF DRUG DELIVERY | ALZA CORPORATION (US) | 1992-10-20 | — | — | US | disclosed |
| WO-1992004011-A1 | DOSAGE FORM FOR TIME-VARYING PATTERNS OF DRUG DELIVERY | ALZA CORPORATION (US) | 1992-03-19 | — | — | WO | disclosed |
| WO-1991014426-A1 | DOSAGE FORM FOR DELIVERING DRUG TO THE INTESTINE | ALZA CORPORATION (US) | 1991-10-03 | — | — | WO | disclosed |
| US-4904474-A | Delivery of drug to colon by oral disage form | ALZA CORPORATION (US) | 1990-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336697-A1 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | CD79B, CD99, BCL6 | NR3C1 624/4885HIF1A 4135/4885HSD17B10 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.